Chinese scientists develop tumor-specific anti-cancer
therapy
Chinese scientists developed a combined tumor-killing therapy that can be activated
specifically at tumor sites in mouse models of cancer, which is more effective
than previous similar therapies. The study published on Friday in the journal
Science Immunology described the new cancer immunotherapy that can prevent the
immune system from becoming tolerant of tumors, which occurs in 30 per cent of
all cancer patients, the Xinhua news agency reported.
A team led by Wang Dangge from Shanghai Institute of
Materia Medica under the Chinese Academy of Sciences and Fudan University developed
a common immune checkpoint inhibitor in a
nanoparticle formulation, which is highly tumor-specific. The checkpoint
inhibitor is a kind of increasingly popular anti-tumor drug. It can block
proteins that keep immune T cells from killing cancer. But the checkpoint
inhibitor used to target those immune system-suppressing proteins like PD-1 and
PD-L1 often fails to reach deep-seated or metastatic tumors.
Wang’s team combined the nanoparticles carrying
PD-L1-targeting antibodies with a light-activated molecule. The molecule called
photosensitiser can produce tumor-killing reactive oxygen species after
encountering a protein abundant in tumors, according to the study. In mouse
models, a local near-infrared radiation that activated the photosensitiser,
along with the administration of antibodies-carrying nanoparticles, promoted the
infiltration of cancer cell-killing T cells into the tumor site and made the
tumors more sensitive to the checkpoint blockade.
This combination also helped the nanoparticles
effectively suppress tumor growth and metastasis to the lung and lymph nodes,
resulting in approximately 80 per cent mouse survival over 70 days, compared to
complete mouse death in 45 days in the group treated with only PD-L1
antibodies, according to the study.
15.07.2019
Knowing is not enough; we must apply, wishing is not enough; we must do
Johann Wolfgang
Von Goethe
No comments:
Post a Comment